We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Speaker: Dr. Ariadna Boloix Amenós, Main researcher Childhood Cancer and Blood Disorders (VHIR)
I am a postdoctoral researcher in the Neural tumors Laboratory in the group of Childhood Cancer and Blood Disorders. Specifically, I am working on project based on the development and implementation of RNA-based therapies in clinical practice for the treatment of pediatric solid tumors. Despite my Pharmacist background, I started my PhD in a collaboration between the Childhood Cancer and Blood Disorders group at VHIR and the Nanomol group at ICMAB-CSIC, focusing on developing a non-liposomal lipid nanocarrier for RNA delivery. After defending my thesis, I continued my work at VHIR, evaluating the effectiveness of the nanomedicine that we have developed from in vitro studies to in vivo models. My goal is to bridge the gap between cutting-edge research and practical clinical applications to benefit young patients.
RNA therapeutics have revolutionized cancer treatment by targeting the entire transcriptome. Small RNA molecules, such as microRNA (miRNA) and small interfering RNA (siRNA), are commonly used in preclinical and clinical settings. However, challenges in stability, biodistribution, and tissue targeting hinder their translation into effective treatments. Nanotechnology offers a promising solution to enhance the efficacy and selectivity of these therapies, particularly in targeting cancer cells. Lipid-based nanovesicles, including liposomes, have been extensively utilized for delivering nucleic acids and were among the first to reach the market. However, the lack of a standardized clinical formulation is a hurdle, mainly due to limited industrial-scale manufacturing capabilities and challenges in tissue specificity. Our objective is to advance the development of a nanomedicine platform utilizing non-liposomal lipid-based nanovesicles known as Quatsomes (QS). This platform aims to deliver small RNAs with tumor-suppressive properties, ultimately improving cancer treatment.
Host: Dr. Miguel Segura Ginard, Main researcher Childhood Cancer and Blood Disorders (VHIR)
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.